Just after ASCO, China’s Legend Biotech raises nearly $424M in initial public offering

Just after ASCO, China’s Legend Biotech raises nearly $424M in initial public offering

Johnson & Johnson, which in-licensed Legend’s CAR-T technology and is developing a version of its product under the name JNJ-4528, presented data from the Phase Ib/II CARTITUDE-1 study at the ASCO meeting.

Source: https://ift.tt/2A18kfa